Currently, three BRAF inhibitors (BRAFi) are clinically approved for the treatment of BRAF-V600E and BRAF-V600K mutant melanoma, namely vemurafenib, dabrafenib, and encorafenib, commonly administered together with the MEK inhibitors (MEKi) cobimentinib, trametinib, or binimetinib, respectively (Larkin et al, 2014; Long et al, 2015; Dummer et al, 2018). This evidence concerns the gene MAP2K7 and melanoma.